Base de dados : LILACS
Pesquisa : C04.557.386.480 [Categoria DeCS]
Referências encontradas : 716 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 72 ir para página                         

  1 / 716 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-601014
Autor: Gouveia, Gisele Rodrigues; Siqueira, Sheila Aparecida Coelho; Chamone, Dalton de Alencar Fischer; Pereira, Juliana.
Título: Prevalence of non-Hodgkin lymphomas in São Paulo, Brazil
Fonte: Rev. bras. hematol. hemoter;33(4):317-317, 2011. ilus.
Idioma: en.
Descritores: Linfoma não Hodgkin
Brasil
Prevalência
Limites: Seres Humanos
Tipo de Publ: Carta
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  2 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Vassallo, José
Alves, Fabio de Abreu
Texto completo
Id: biblio-1021053
Autor: Siqueira, Juliana Mota; Fernandes, Patrícia Maria; Oliveira, Andrea Cruz Ferraz de; Vassallo, José; Alves, Fábio de Abreu; Jaguar, Graziella Chagas.
Título: Primary diffuse large B-cell lymphoma of the mandible
Fonte: Autops. Case Rep;9(3):e2019109, July-Sept. 2019. ilus.
Idioma: en.
Resumo: Primary intraosseous non-Hodgkin lymphoma in the mandible is uncommon, representing about 0.6% of all extranodal lymphomas. We present the case of a 51-year-old male with a 4-month complaint of mandibular swelling and paresthesia, which had been previously submitted to an unsuccessful periodontal treatment. The intra-oral evaluation showed an extensive swelling with teeth mobility in the right mandible body. The panoramic radiography and computed tomography images showed an extensive osteolytic lesion. An incisional biopsy was performed and the histopathological and immunohistochemical analysis established the diagnosis of diffuse large B-cell lymphoma. The treatment included six cycles of chemotherapy with complete remission. The patient is under the seventh month of follow-up with no evidence of relapse. Although uncommon in the oral cavity, lymphoma should be considered in the differential diagnosis.
Descritores: Linfoma Difuso de Grandes Células B/patologia
Neoplasias de Cabeça e Pescoço/patologia
-Linfoma não Hodgkin
Medicina Bucal
Diagnóstico Diferencial
Mandíbula
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Conferência Clínica
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  3 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1020995
Autor: Rogers, Thomas S; Gardner, Juli-Anne; Devitt, Katherine A.
Título: High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia
Fonte: Autops. Case Rep;9(3):e2019090, July-Sept. 2019. ilus, graf.
Idioma: en.
Resumo: Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly "double-hit" and "triple-hit" lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a "double-hit" lymphoma genotype.
Descritores: Linfoma Difuso de Grandes Células B/patologia
-Linfoma não Hodgkin
Leucemia Linfocítica Crônica de Células B
Citogenética
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Conferência Clínica
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  4 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Viana, Marcos Borato
Texto completo
Texto completo
Id: lil-654978
Autor: Cunha, Keyla Christy Christine Mendes Sampaio; Oliveira, Maria Christina Lopes Araujo; Gomes, Ana Cecília Silva; Castro, Lucia Porto Fonseca de; Viana, Marcos Borato.
Título: Clinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in Brazil
Fonte: Rev. bras. hematol. hemoter;34(5):361-366, 2012. graf, tab.
Idioma: en.
Resumo: OBJECTIVE: Burkitt's lymphoma is the most common subtype of non-Hodgkin lymphoma in children. The aim of this study was to characterize the clinical course and prognostic factors of children and adolescents with Burkitt's lymphoma treated in the Hematology Unit of Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG). METHODS: A retrospective cohort study was made of 50 consecutive cases of children and adolescents aged 16 years or less with Burkitt's lymphoma admitted between January 1981 and December 2007. Prognostic factors associated with death were evaluated using the Kaplan-Meier method and compared by the two-tailed log-rank test. RESULTS: The median age at diagnosis was 4.7 years. Most patients had abdominal tumors (66.7%) and advanced disease (68.9%) at diagnosis. Thirty-eight patients (84.4%) achieved complete clinical remission and 33 (73.3%) were alive at the first remission. Twelve children (26.7%) died. The median follow-up was 35 months with the probability of overall survival being 73% (89.2% and 35.7% for patients with uric acid < 7 mg/dL and > 7.0 mg/dL, respectively - p-value < 0.001). Uric acid was the only significant prognostic factor at diagnosis. CONCLUSION: Our findings confirm the favorable prognosis of children with Burkitt's lymphoma even when treated with intermediate doses of methotrexate (500 mg/m2). Survival was significantly lower for individuals with concentrations of uric acid > 7 mg/dL.
Descritores: Prognóstico
Sobrevida
Ácido Úrico
Linfoma não Hodgkin
Criança
Linfoma de Burkitt
Limites: Seres Humanos
Masculino
Feminino
Pré-Escolar
Criança
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  5 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1036
Autor: Rebelo, Bianca Rosa Rodrigues; Castro, Laize Mariane Gonçalves Silva; Oliveira, Paula Malagoni Cavalcante; Cardoso, Daniela Medeiros Milhomem; Silvério, Américo de Oliveira.
Título: Estenose de esôfago como manifestação de amiloidose esofágica / Stenosis esophagus as expression of systemic amyloidosis
Fonte: GED gastroenterol. endosc. dig;35(2):63-69, abr.-jun. 2016. ilus.
Idioma: pt.
Resumo: Amiloidose é o depósito anormal extracelular de substância proteica fibrilar, insolúvel, mais comum em idosos, que pode ser resultado de um grande e heterogêneo grupo de transtornos e pode gerar danos e disfunção de variados órgãos potencialmente envolvidos. O envolvimento esofágico da amiloidose é incomum, assim como a epiglote, não é habitualmente foco primário de um linfoma não-Hodgkin (LNH). O presente relato apresenta um caso incomum de amiloidose esofágica relacionada à tuberculose pulmonar e ao linfoma não-Hodgkin de epiglote. Paciente de 79 anos, com queixa de disfagia progressiva e disfonia, há 2 anos. Radiografia contrastada de esôfago revelou estenose com irregularidade da mucosa no 1/3 superior de esôfago e a endoscopia digestiva alta evidenciou lesão infiltrativa e estenosante de esôfago torácico superior e médio, com aspecto neoplásico; porém, anatomopatológico das biópsias evidenciou mucosa escamosa própria do esôfago com acantose, papilomatose, apresentando, abaixo da mucosa, material amorfo eosinofílico e fragmentado que, após aplicação de corantes especiais (Vermelho Congo e Cristal Violeta), revelou tratar-se de depósito amiloide, confirmado por análise imuno-histoquímica. Durante investigação de outros órgãos acometidos, diagnosticado envolvimento linfonodal e pulmonar. Tentado tratamento sintomático do quadro de disfagia com dilatação com vela de Savary, além de uso de colchicina como tentativa de reduzir deposição de amiloide. Mais tarde, em investigação da etiologia da doença, descoberto Linfoma Não-Hodgkin de epiglote e tuberculose pulmonar como possíveis causas da mesma, sendo então encaminhada para tratamento quimioterápico e antituberculínico.

The lack of therapeutic options for celiac disease (CD) has become a relevant issue in the pharmaceutical sector, as a result of the improvement on technical diagnostic serological and the following increase in the number of individuals with confirmed diagnosis for this disease. To date, the only effective therapy to CD is the gluten-free diet, a seemingly simple treatment, but that has enormous repercussions in the social and nutritional habits of the patient. New findings on the complex pathogenic mechanism of CD allowed gradually the development of researches to look for new therapeutic options, among which we can highlight the oral intake of enzymes capable to hydrolyze the gluten, inhibitors of tissue transglutaminase enzyme, inhibitors of intestinal permeability, and tolerance induction of gluten. This study, besides to describing some features of celiac disease and its relationship with the structure of gluten, compiles information from several authors regarding the development of new treatment of this disease, with the goal of identifying therapeutic options that present the biggest advances and, therefore, has the potential to be at the disposal of celiac patients in a near future.
Descritores: Tuberculose Pulmonar
Linfoma não Hodgkin
Epiglote
Estenose Esofágica
Esôfago
Amiloidose
Limites: Seres Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: BR9.1 - Biblioteca de Ciências da Saúde Profa. Susana Schimidt


  6 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-960435
Autor: Fernández Águila, Julio D; García Vega, Yanelda de los Ángeles; Hernández Casaña, Patricia; Hernández Cruz, Calixto; Medina Rodríguez, Bárbaro Andrés; Viada González, Carmen Elena.
Título: Seguridad y efecto del uso compasivo del anticuerpo monoclonal anti-CD20 CIMABior® / Safety and response to treatment of compassionate use of an anti-CD20 monoclonal antibody CIMABior®
Fonte: Rev. cuba. hematol. inmunol. hemoter;33(4):35-49, oct.-dic. 2017. tab.
Idioma: es.
Resumo: Introducción: el uso de anticuerpos monoclonales transformó el tratamiento de los linfomas no hodgkinianos. El Centro de Inmunología Molecular generó un anticuerpo anti-CD20 (CIMABior®) biosimilar del rituximab, que se ha caracterizado desde el punto de vista biológico, pero la seguridad y eficacia aún están en estudio. Objetivo: evaluar la seguridad y la respuesta al tratamiento con CIMABior ®, en pacientes con síndromes linfoproliferativos de células B tratados con intención compasiva. Métodos: estudio multicéntrico, exploratorio, con dos grupos de tratamiento (monoterapia o combinado con quimioterapia) no controlado, ni aleatorizado. Se incluyeron adultos con linfomas no hodgkinianos y leucemia linfocítica crónica, no elegibles para el ensayo clínico en ejecución con este producto. Se determinó la frecuencia de eventos adversos y se caracterizaron. La respuesta al tratamiento se definió como: remisión completa, remisión parcial, enfermedad estable o en progresión. Se calculó la tasa de respuesta objetiva (remisión completa más remisión parcial) con el intervalo de confianza al 95 por ciento, se evaluó la relación de algunas variables con la respuesta y se estimó la razón de Odss. Como medida de balance beneficio-riesgo se estimó el factor de Bayes. Resultados: los eventos adversos más frecuentes fueron: temblor (12,8 por ciento) y fiebre (10,3 por ciento). Los relacionados con el producto (43,4 por ciento) fueron leves o moderados y evolucionaron hacia la recuperación. No se informó muerte asociada directamente al tratamiento. Se constató respuesta objetiva global de 71,2 por ciento (59,6 por ciento de remisiones completas y 11,5 por ciento, parciales). La respuesta objetiva en el grupo de monoterapia fue de 66,7 por ciento y de 73,0 por ciento en el grupo de CIMABior® más quimioterapia, con remisiones completas de 46,7 por ciento y 64,9 por ciento, respectivamente. Conclusiones: el AcM CIMABior® es seguro, bien tolerado y se demostraron evidencias de efecto. El tratamiento aportó un beneficio clínico superior al riesgo de desarrollar algún evento adverso grave(AU)

Introduction : The use of monoclonal antibodies transformed the treatment of non-Hodgkin lymphomas. The Center of Molecular Immunology created an anti-CD20 monoclonal antibody (CIMABior®), biosimilar of rituximab, which has been characterized from a biological point of view, but the safety and effectiveness are still being studied. Objective: Evaluate the safety and response to treatment, in patients with B-cell malignancies with compassionate use of CIMABior®. Methods : A multicenter, exploratory, non-controlled, non-randomized study was conducted with two variants of treatments (monotherapy or combined with chemotherapy). Adults with non-Hodgkin lymphomas and chronic lymphocytic leukemia not eligible for clinical trial with this product were included. Frequency of adverse events was calculated and those were characterized. The response to treatment was defined as: complete response, partial response, stable disease or progressive disease. Overall response rate (complete plus partial remission) was calculated with 95 percent confidence interval. The relation of some variables with response was estimated per Odss ratio. As a measure of the benefit-risk balance, the Bayes factor was estimated. Results : The more frequent adverse events were: tremors (12.8 percent) and fever (10.3 percent). Those related to the product (43.4 percent) were minor and evolved to recovery. There were no deaths in reference to the treatment. An overall response of 71.2 percent was confirmed (59.6 percent complete remissions and 11.5 percent partial remission). The monotherapy group objective response was 66.7 percent and 73.0 percent in the CIMABior® plus chemotherapy group, with complete remissions of 46.7 percent and 64.9 percent respectively. Conclusions: The monoclonal antibodies CIMABor® is safe, well tolerated and evidences of its effectiveness was demonstrated. The treatment provided a superior clinical benefit to the risk of developing a severe adverse event(AU)
Descritores: Linfoma não Hodgkin/terapia
Leucemia de Células B/terapia
-Resultado do Tratamento
Cuba
Ensaios de Uso Compassivo/ética
Citometria de Fluxo/métodos
Antineoplásicos Imunológicos/uso terapêutico
Anticorpos/uso terapêutico
Limites: Seres Humanos
Masculino
Feminino
Responsável: CU1.1 - Biblioteca Médica Nacional


  7 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1009652
Autor: Siso, Royfel; Puerta, Augusto; M, Melva Franklin; Montes de Oca, Ivette; Parejo, José Antonio; Reyes, Heidi.
Título: Coccidiodomicosis diseminada: reporte de un caso en miranda / Diseminated coccidiodomicosis: report of a case in estado miranda, Venezuela
Fonte: Med. interna (Caracas);31(4):206-210, 2015. ilus, tab.
Idioma: es.
Resumo: Se presenta el caso de un hombre de 46 años con antecedente de linfoma de Hodgkin, cuya enfermedad actual comienza 6 meses previos a su ingreso con diarrea y fiebre, sin moco ni sangre. Un mes más tarde se asocia rinorrea verdosa acompañada de tos no productiva, sintomatología que persistió en el tiempo por lo cual acude a nuestro centro. Al examen físico se evidenciaron lesiones costrosas a nivel de la mucosa nasal de las cuales se tomaron muestras para biopsia y cultivo, aislándose en el cultivo Coccidiodes inmitis. La Coccidiodomicosis es una infección poco frecuente dentro de las micosis profunda, es endémica en Estados Unidos en Arizona y California. En Venezuela se han reportado pocos casos, únicamente en 3 estados: Lara, Zulia y Falcón. El paciente vive en Guarenas, negó viajes fuera del área de Miranda en los últimos 10 años y su ocupación es recolectar bolsas en supermercado. Posterior a los hallazgos clínicos, paraclínicos y revisión bibliográfica, se concluye como el primer caso reportado de Coccidiodomicosis diseminada en el estado Miranda(AU)

We present the case a 46 year- old man with a history of Hodgkin´s lymphoma, who refers 6 months before admission, watery stools without mucus or blood and fever. One month after the onset of the gastrointestinal symptoms, he presented nasal discharge and nonproductive cough, which persisted until he consulted to our hospital. On physical examination scabby lesions in nasal mucosa were found, biopsy and culture samples were taken. The culture reported Coccidiodes immitis. Coccidioidomycosis is a rare deep mycosis infection; it is endemic in the United States in Arizona and California. In Venezuela cases have been reported only in 3 states: Lara, Zulia and Falcon and he denied, trips outside the area in the last 10 years. He worked as and collector in a supermarket. This is the first reported case of disseminated coccidioidomycosis in Miranda state(AU)
Descritores: Linfoma não Hodgkin/patologia
Coccidiose/fisiopatologia
Coccidiose/tratamento farmacológico
-Medicina Interna
Micologia
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha


  8 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1008289
Autor: Caltagirone, Raimondo; Dulcey, Luís; González, Jesús; García, Jair; Díaz, Aixa; León, César; Cordero, Javier; Pineda, Jonathan; Sampayo, José; Luces, Claire; Moreno, Hector.
Título: Linfoma no Hodgkin primario testicular / Non hodgkin primary testicular limphoma
Fonte: Med. interna (Caracas);34(1):57-60, 2018. ilus.
Idioma: es.
Resumo: Los linfomas constituyen un grupo diverso de neoplasias malignas, que se originan del sistema linfático(1). Aproximadamente el 85% se agrupan dentro de los denominados Linfomas No Hodgkin (LNH). Los LNH constituyen un numeroso grupo de linfomas derivados de la transformación neoplásica de los linfocitos B, T y Células NK, provenientes de diversas zonas que comprometen los folículos linfáticos en los nódulos linfáticos o en el sistema linfoide extranodal(2). Las localizaciones extra ganglionares primarias representan más de 10% de los casos y los sitios más frecuentes comprenden estómago, intestino delgado, orofaringe, piel, hígado y cerebro; además de otras bastante raras como ano, corazón, músculos y encías. Los linfomas testiculares primarios son muy raros, representan aproximadamente el 5% de todas las neoplasias testiculares malignas, menos del 1% de los LNH y el 4% de los LNH extra nodales(3). Esta neoplasia constituye el tumor maligno testicular más frecuente en sujetos ancianos. La presentación clínica típica es una masa testicular unilateral acompañada en ocasiones de hidrocele y dolor agudo escrotal. A continuación presentamos un caso que requirió de la participación de múltiples especialidades de nuestra institución para un manejo conjunto y finalmente el paciente falleció(AU)

The lymphomas constitute a diverse group of malignant neoplasms, which originate from the lymphatic system(1). Approximately 85% are grouped into the so-called Non-Hodgkin's Lymphomas (NHL). NHL are a large group of lymphomas derived from the neoplastic transformation of B, T and NK cells of different areas with involvement of lymphatic follicles in the lymph nodes or the extranodal lymphoid system(2). The primary extraganglionic sites represent more than 10% of the cases and the most frequent sites include stomach, small intestine, oropharynx, skin, liver and brain; others, quite rare, are anus, heart, muscles and gums.Primary testicular lymphomas are extremely rare, accounting for approximately 5% of all malignant testicular neoplasms, less than 1% of NHL and 4% of extranodal NHL(3). This neoplasm constitutes the most frequent testicular malignant tumor in elderly subjects. The typical clinical presentation is a unilateral testicular mass, sometimes accompanied by hydrocele and acute scrotal pain. We present a case which required the participation of multiple specialties of our institution for management but the patient finally died(AU)
Descritores: Neoplasias Testiculares/etiologia
Linfoma não Hodgkin/patologia
Sistema Linfático/patologia
-Linfócitos
Medicina Interna
Oncologia
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha


  9 / 716 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Texto completo
Id: biblio-898917
Autor: Santos, Tayse Silva dos; Tavares, Renato Sampaio; Farias, Danielle Leão Cordeiro de.
Título: Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges
Fonte: Rev. bras. hematol. hemoter;39(2):146-154, Apr.-June 2017. tab, ilus.
Idioma: en.
Resumo: ABSTRACT Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.
Descritores: Prognóstico
Neoplasias Esplênicas
Esplenomegalia
Linfoma não Hodgkin
Linfoma de Zona Marginal Tipo Células B/diagnóstico
Linfoma de Zona Marginal Tipo Células B/terapia
Tipo de Publ: Revisão
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  10 / 716 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-679047
Autor: Osorio M, Jaime; Faraggi A, Marcelo; Cardemil M, Felipe.
Título: Linfoma no Hodgkin laríngeo: reporte de un caso / Laryngeal non Hodgkin lymphoma: case report
Fonte: Rev. otorrinolaringol. cir. cabeza cuello;73(1):73-78, abr. 2013. ilus.
Idioma: es.
Resumo: Los linfomas de la laringe son infrecuentes, correspondiendo a menos del 1% de las neoplasias de esta ubicación. La detección temprana puede permitir una mejor atención y eventualmente un mejor pronóstico. Se presenta un caso de linfoma no Hodgkin supraglótico derecho, correspondiente a una paciente de sexo femenino de 68 años, que consulta por disfonía progresiva de varios meses de evolución que se intensifica durante el último mes. La nasofibroscopía mostró una lesión tumoral que comprometía el repliegue aritenoepiglótico derecho, con mucosa sana. La tomografía axial computarizada objetivó un tumor de hemilaringe derecha de aspecto sólido que se extendía desde la base de la epiglotis hasta la glotis. La resonancia magnética informó un proceso expansivo que comprometía la región supraglótica derecha, de aspecto benigno, sin infiltración. Se extirpó un tumor submucoso en su totalidad por tirotomía media. En el examen histopatológico se observaron elementos compatibles con linfoma no Hodgkin difuso, lo que fue confirmado por técnica de inmunohistoquímica. Se trató con esquema CHOP de quimioterapia. No ha habido recidiva tumoral al 3° año de seguimiento. Los linfomas no Hodgkin de laringe son poco frecuentes. Se describen las características y manejo de este tipo de tumores.

Lymphomas of the larynx are rare, accounting for less than 1%% of neoplasms in this location. Early detection can allow better care, and possibly a better prognosis. We present a case of a right supraglottic Non-Hodgkin Lymphoma, corresponding to a female patient of 68 years who consulted for hoarseness of several months that progressed during the last month. Fibroscopic evaluation showed a tumor involving the right aryepiglottic fold, without mucosal lesion. Computed tomography showed a solid tumor of the right hemilarynx, that extends from base of epiglottis to glottis. Magnetic resonance showed tumor expansion process that involves the right epiglottic region, of benign appearence, without infiltration. We perform a complete removal of the submucosal tumor externally by a medial laryngeal thyroidotomy. Histopathological examination showed elements compatible with diffuse Non-Hodgkin Lymphoma, which was confirmed by immunohistochemestry. CHOP chemotherapy was indicated. Currently, patient followed up for 3 years, with no signs of tumor recurrence. Non-Hodgkin Lymphomas of the larynx are rare. We describe the characteristics and management of these tumors.
Descritores: Linfoma não Hodgkin/cirurgia
Linfoma não Hodgkin/diagnóstico
Neoplasias Laríngeas/cirurgia
Neoplasias Laríngeas/diagnóstico
-Linfoma não Hodgkin/tratamento farmacológico
Imuno-Histoquímica
Imagem por Ressonância Magnética
Tomografia Computadorizada por Raios X
Neoplasias Laríngeas/tratamento farmacológico
Disfonia/etiologia
Limites: Seres Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Responsável: CL30.1 - Biblioteca



página 1 de 72 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde